Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25829683 | 0.82 | KMT2A (0.52) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL21962922 | 0.79 | KMT2A (0.57) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL22010526 | 0.79 | POLB (0.44) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL22010522 | 0.78 | POLB (0.39) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL25829889 | 0.77 | MEN1 (0.43) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL7269972 | 0.76 | POLB (0.48) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL21962937 | 0.75 | KMT2A (0.51) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL7332197 | 0.73 | KMT2A (0.50) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL7335528 | 0.73 | KMT2A (0.50) | KMT2AMEN1POLBCA9CA2 | |
| SCHEMBL7415092 | 0.72 | KMT2A (0.52) | KMT2AMEN1POLBCA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102100-A9 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-01-06 | — | — | WO | disclosed |
| WO-2020102100-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |